Alto Neuroscience, Inc.

NYSE:ANRO

Biotechnology

Healthcare
$25.91 +1.84%

+$0.40 today

Market cap
$1.04B
Beta
1.25
P/E (TTM)
-9.8
EPS (TTM)
-$2.26
52W Low $2.15High $28.44

Volume 0.99M

Average 0.34M

Returns on capital

Alto Neuroscience, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management

ROE

-41.8%

avg 22.8%

ROIC

-38.2%

avg -46.8%

ROA

-34.2%

avg -39.4%

Analysis

ROA is currently the strongest return metric at -34.2% versus its period average of -39.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Amit Etkin

Founder, CEO & Chairman of the BoardUSD 1.25M49833.95K2.38%

Nicholas C. Smith

CFO & PresidentUSD 946.86K37——

Michael C. Hanley

Chief Operating OfficerUSD 695.33K52——

Adam Savitz

Chief Medical OfficerUSD 579.57K60124.00K0.35%

Dan Segal

Co-Founder & Strategic Advisor—64——

Erin R. McQuade

General Counsel, Chief Administrative Officer & Corporate Secretary—51——

Jessica Powell

Chief Development Officer—51——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding May 14, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

3

$3.57M

Net Transaction Value

−$3.57M

Net selling

Most Active

Smith Nicholas Conrad

3 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Sep 30, 26

Smith Nicholas Conrad

Direct

Sell$597.3K
Sep 30, 26

Smith Nicholas Conrad

Direct

Sell$23.8K
Sep 29, 26

Smith Nicholas Conrad

Direct

Sell$2.9M

Summary

Insiders reported 0 buys worth $0.00 and 3 sells worth $3.57M over the last 12 months. That adds up to net selling of $3.57M. Smith Nicholas Conrad was the most active insider with 3 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A5 analysts
RevenueN/AN/AN/A
N/A6 analysts
Net IncomeN/AN/AN/A
N/A6 analysts
EBITN/AN/AN/A
N/A6 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Alto Neuroscience, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ANRO's management, answered from reported figures.

Who manages ANRO?

Alto Neuroscience, Inc. (ANRO) lists 7 active executives. The top listed executive is Amit Etkin, Founder, CEO & Chairman of the Board.

Are ANRO insiders buying or selling?

Recent insider activity shows net buying of $25.65M.